文献速递衰弱、肌少症与跌倒老年慢病共病管理老年综合评估

糖尿病患者的衰弱测量、患病率、发病率及临床意义:系统综述与研级荟萃分析

Frailty measurement, prevalence, incidence, and clinical implications in people with diabetes: a systematic review and study-level meta-analysis.
PubMed 文献 · Lancet Healthy Longev · 2020-01-01

该系统综述与研级荟萃分析纳入118项观察性研究、共1 375 373名成年糖尿病患者,使用20种衰弱测量工具;社区人群中衰弱表型的中位患病率为13%(IQR 9-21)。

要点

  • 社区糖尿病患者使用衰弱表型的中位衰弱患病率为13%(IQR 9-21)。
  • 衰弱与低血糖事件、并发症、生活质量下降及认知障碍相关,与糖化血红蛋白关系不一致。

核心结论

  • 衰弱与糖尿病患者死亡、住院、残疾、低血糖事件、微血管和大血管并发症、生活质量下降及认知障碍相关。
  • 衰弱与糖化血红蛋白之间未发现一致关系。
  • 衰弱的识别与评估应成为糖尿病诊疗的常规组成部分。

研究设计与样本

  • 系统综述与研级荟萃分析,检索MEDLINE、Embase和Web of Science自2001年1月1日至2019年11月26日的观察性研究。
  • 纳入评估并量化18岁及以上成人糖尿病患者衰弱的研究,排除会议摘要、灰色文献及非英文发表研究。
  • 共纳入118项研究、使用20种衰弱测量工具,样本量n=1 375 373。
  • 主要结局为糖尿病患者衰弱患病率;次要结局为衰弱发病率及一般结局和糖尿病特异性结局。
  • 因研究异质性大,主要结局采用叙述性综合,可行时采用随机效应荟萃分析;研究注册号PROSPERO CRD42020163109。

主要发现

  • 最常用的衰弱测量工具为衰弱表型(69/118项研究,58%)、衰弱(16/118项研究,14%)和FRAIL量表(10/118项研究,8%)。
  • 研究设置异质:88项基于社区、18项基于门诊、10项基于住院、2项基于住宿照护机构。
  • 社区人群使用衰弱表型的中位衰弱患病率为13%(IQR 9-21)。
  • 7项(100%)研究显示衰弱与住院相关,5项(100%)研究显示衰弱与残疾相关。

关键数值与推荐

  • 社区糖尿病患者使用衰弱表型的中位衰弱患病率为13%(IQR 9-21)。
  • 推荐将衰弱的识别与评估作为糖尿病诊疗的常规组成部分。
  • 需进一步理解衰弱与血糖的关系以及衰弱在特定人群(如中年<65岁人群及低收入和中低收入国家人群)中的影响,以便制定针对衰弱个体的糖尿病指南。

临床怎么用

  • 在糖尿病诊疗中应常规识别和评估衰弱。
  • 对衰弱糖尿病患者需关注死亡、住院、残疾、低血糖事件、并发症、生活质量下降及认知障碍等不良结局风险。
  • 不应仅依据糖化血红蛋白管理衰弱糖尿病患者,因衰弱与糖化血红蛋白关系不一致。

局限性

  • 研究在设置、人口学和纳入标准方面异质性大,主要结局未能进行荟萃分析。
  • 衰弱测量工具多样(共20种),不同工具间结果可能不可比。
  • 评估衰弱与低血糖事件关系的研究仅1项(<1%),证据有限。
  • 评估糖化血红蛋白与衰弱关系的研究仅13项(11%),未发现一致关系。
  • 特定人群(如中年<65岁人群及低收入和中低收入国家人群)中衰弱的影响尚需更好理解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Frailty, a state of increased vulnerability to adverse health outcomes, is important in diabetes management. We aimed to quantify the prevalence of frailty in people with diabetes, and to summarise the association between frailty and generic outcomes (eg, mortality) and diabetes-specific outcomes (eg, hypoglycaemia). METHODS: In this systematic review and study-level meta-analysis, we searched MEDLINE, Embase, and Web of Science for observational studies published between Jan 1, 2001 (the year of the original publication of the Fried frailty phenotype), to Nov 26, 2019. We included studies that assessed and quantified frailty in adults with diabetes, aged 18 years and older; and excluded conference abstracts, grey literature, and studies not published in English. Data from eligible studies were extracted using a piloted data extraction form. Our primary outcome was the prevalence of frailty in people with diabetes. Secondary outcomes were incidence of frailty and generic and diabetes-specific outcomes. Data were assessed by random-effects meta-analysis where possible and by narrative synthesis where populations were too heterogeneous to allow meta-analysis. This study is registered with PROSPERO, CRD42020163109. FINDINGS: Of the 3038 studies we identified, 118 studies using 20 different frailty measures were eligible for inclusion (n=1 375 373). The most commonly used measures of frailty were the frailty phenotype (69 [58%] of 118 studies), frailty (16 [14%]), and FRAIL scale (10 [8%]). Studies were heterogenous in setting (88 studies were community-based, 18 were outpatient-based, ten were inpatient-based, and two were based in residential care facilities), demographics, and inclusion criteria; therefore, we could not do a meta-analysis for the primary outcome and instead summarised prevalence data using a narrative synthesis. Median community frailty prevalence using frailty phenotype was 13% (IQR 9-21). Frailty was consistently associated with mortality in 13 (93%) of 14 studies assessing this outcome (pooled hazard ratio 1·51 [95% CI 1·30-1·76]), with hospital admission in seven (100%) of seven, and with disability in five (100%) of five studies. Frailty was associated with hypoglycaemia events in one study (<1%), microvascular and macrovascular complications in nine (82%) of 11 studies assessing complications, lower quality of life in three (100%) of three studies assessing quality of life, and cognitive impairment in three (100%) of three studies assessing cognitive impairment. 13 (11%) of 118 studies assessed glycated haemoglobin finding no consistent relationship with frailty. INTERPRETATION: The identification and assessment of frailty should become a routine aspect of diabetes care. The relationship between frailty and glycaemia, and the effect of frailty in specific groups (eg, middle-aged [aged <65 years] people and people in low-income and lower-middle-income countries) needs to be better understood to enable diabetes guidelines to be tailored to individuals with frailty. FUNDING: Medical Research Council.

来源:Lancet Healthy Longev,查看原文。版权归原作者所有。

引用

  1. Hanlon P, Fauré I, Corcoran N, et al. Frailty measurement, prevalence, incidence, and clinical implications in people with diabetes: a systematic review and study-level meta-analysis. Lancet Healthy Longev. 2020. PMID: 33313578. doi:10.1016/S2666-7568(20)30014-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。